03.01.19
Professional skincare company Biopelle, Inc. has unveiled Emepelle, which it calls the first and only clinically proven1 skin care line that safely and effectively helps address estrogen deficient skin (EDS).The Ferndale, MI-based company is unveiling the new range at the American Academy of Dermatology (AAD) meeting in Washington D.C., which gets underway today.
Emepelle is powered by MEP Technology, a patented, specifically designed ingredient that helps to non-hormonally restore the natural function of Estrogen Deficient Skin, according to Biopelle.
Estrogen loss is a primary cause of accelerated collagen loss and skin aging in women. Low estrogen results in skin dryness, atrophy, wrinkling and thinning. In the first five years of menopause low estrogen levels lead to a staggering 30% loss of the skin's collagen and a subsequent 2.1% loss each year thereafter.2
The Emepelle product line consists of a serum and a night cream; both feature MEP Technology and other proven ingredients to help provide additional anti-aging benefits, said the company. The products work on all skin types and are recommended for women who are in perimenopause or menopause.
"We are thrilled to announce the introduction of Emepelle for women with Estrogen Deficient Skin, a condition that affects millions of women in the U.S.," said Eric Fleming, president and COO of Biopelle, Inc. "At this time, there are no cosmeceuticals available that are clinically proven to safely and effectively help address estrogen deficiency of the skin. We are excited that there is finally a product that can empower women and help them manage the aging process of their skin more confidently."
Emepelle is powered by MEP Technology, a patented, specifically designed ingredient that helps to non-hormonally restore the natural function of Estrogen Deficient Skin, according to Biopelle.
Estrogen loss is a primary cause of accelerated collagen loss and skin aging in women. Low estrogen results in skin dryness, atrophy, wrinkling and thinning. In the first five years of menopause low estrogen levels lead to a staggering 30% loss of the skin's collagen and a subsequent 2.1% loss each year thereafter.2
The Emepelle product line consists of a serum and a night cream; both feature MEP Technology and other proven ingredients to help provide additional anti-aging benefits, said the company. The products work on all skin types and are recommended for women who are in perimenopause or menopause.
"We are thrilled to announce the introduction of Emepelle for women with Estrogen Deficient Skin, a condition that affects millions of women in the U.S.," said Eric Fleming, president and COO of Biopelle, Inc. "At this time, there are no cosmeceuticals available that are clinically proven to safely and effectively help address estrogen deficiency of the skin. We are excited that there is finally a product that can empower women and help them manage the aging process of their skin more confidently."